SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 12, 2018--
Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company discovering and developing innovative
immuno-oncology protein therapeutics, today announced that Aron
Knickerbocker, Chief Executive Officer, will present at the 37th
Annual J.P. Morgan Healthcare Conference, Wednesday, January 9, 2019 at
2:00 pm PT.
The presentation will be webcast and may be accessed at the “Events &
Presentations” section of the Company’s website at http://investor.fiveprime.com/events.cfm.
Five Prime will maintain an archived replay of the webcast on its
website for 30 days after the conference.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious diseases.
Five Prime's comprehensive discovery platform, which encompasses
virtually every medically relevant extracellular protein, positions it
to explore pathways in cancer, inflammation and their intersection in
immuno-oncology, an area with significant therapeutic potential and the
focus of the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical companies
and has promising product candidates in clinical and preclinical
development. For more information, please visit www.fiveprime.com
or follow us on LinkedIn,
View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005742/en/
Source: Five Prime Therapeutics, Inc.
Derek Cole, President
Investor Relations Advisory Solutions